This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Prognosis

Authoring team

This is improving with most children reaching early adulthood.

The current median age of those who have died is 28 years and the median predicted survival is 45.1 years (1).

FEV1 is a key predictor of life expectancy in people with cystic fibrosis, and optimising lung function is a major goal of care (1).

The improvement in life expectancy is likely to be a result of improved nutritional status, physiotherapy and antibiotic treatment.

The variability in survival with this disease may reflect a variable expression of the condition and an environmental contribution to the development of clinical manifestations.

Patients may be a candidate for a heart–lung transplant operation.

 

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.